Advancing evidence-based indication prioritization to navigate disease segmentation landscape

Innovation in genomic technologies over the past two decades has ushered in an explosion of new drug targets for drug discovery.

Read more >

DCAT Week '16: Pharmaceutical Outsourcing - The Markets and Supply Strategies for Fine Chemicals, APIs, and Drug Products

The balance between internal manufacturing and development and external sourcing for APIs, fine chemicals, and drug products is a difficult task to manage. This is further complicated by the increasing M&A activity and complexities within the supply chain forcing each company to strongly evaluate their partners and what they choose to produce in house or source through 3rd party vendors.

Read more >

When So Much Depends on So Much: Optimizing Data Integration in the Bioinformatics Community

Innovation is the life blood of the pharmaceutical industry, and innovation runs on data.

Read more >

Innovation and Investment: Challenge and Opportunity for European Biopharma

Read more >

Value, Validation Mark Upbeat State of Industry in Regenerative Medicine

In delivering the Alliance for Regenerative Medicine’s (ARM) 2016 state of the industry briefing at the Biotech Showcase event this month in San Francisco, chair of the international advocacy organization representing the regenerative medicine and advanced therapies (RM/AT) community, Edward Lanphier, said 2015 had been a great year for the sector, exemplified by excellent clinical data readouts that have helped attract significant investments and big pharma validation through major partnerships.

Read more >